ONCOGENEX PHARMACEUTICALS IN's ticker is OGXI and the CUSIP is 68230A106. A total of 68 filers reported holding ONCOGENEX PHARMACEUTICALS IN in Q4 2013. The put-call ratio across all filers is 38.60 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $1,000 | -50.0% | 3,573 | 0.0% | 0.00% | – |
| Q1 2017 | $2,000 | 0.0% | 3,573 | 0.0% | 0.00% | – |
| Q4 2016 | $2,000 | 0.0% | 3,573 | 0.0% | 0.00% | – |
| Q3 2016 | $2,000 | -50.0% | 3,573 | 0.0% | 0.00% | – |
| Q2 2016 | $4,000 | -81.8% | 3,573 | -80.7% | 0.00% | – |
| Q4 2015 | $22,000 | -18.5% | 18,478 | +52.2% | 0.00% | – |
| Q3 2015 | $27,000 | +1250.0% | 12,138 | +1621.7% | 0.00% | – |
| Q2 2015 | $2,000 | -94.6% | 705 | -95.7% | 0.00% | -100.0% |
| Q4 2014 | $37,000 | +12.1% | 16,242 | +30.9% | 0.00% | 0.0% |
| Q3 2014 | $33,000 | -85.1% | 12,412 | -79.0% | 0.00% | -66.7% |
| Q2 2014 | $221,000 | -70.3% | 59,212 | -6.6% | 0.00% | -76.9% |
| Q1 2014 | $745,000 | +1360.8% | 63,386 | +937.1% | 0.01% | +1200.0% |
| Q4 2013 | $51,000 | +54.5% | 6,112 | +72.6% | 0.00% | 0.0% |
| Q3 2013 | $33,000 | -41.1% | 3,541 | -38.3% | 0.00% | 0.0% |
| Q2 2013 | $56,000 | – | 5,741 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 396,104 | $400,000 | 0.42% |
| Ancora Advisors LLC | 50,865 | $51,000 | 0.01% |
| EAGLE GLOBAL ADVISORS LLC | 145,710 | $146,000 | 0.00% |
| Acrospire Investment Management LLC | 5,200 | $5,000 | 0.00% |
| A.R.T. Advisors, LLC | 57,954 | $57,000 | 0.00% |
| Renaissance Technologies | 876,100 | $876,000 | 0.00% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 4,600 | $5,000 | 0.00% |
| Cutler Group LLC / CA | 11,048 | $11,000 | 0.00% |
| PANAGORA ASSET MANAGEMENT INC | 133,846 | $134,000 | 0.00% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 46,100 | $46,000 | 0.00% |